Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Takeuchi, Tsutomu
Atsumi, Tatsuya
Combe, Bernard G.
Aletaha, Daniel
Kaise, Toshihiko
Rajendran, Vijay
Funding for this research was provided by:
Eisai Co., Ltd.
Gilead Sciences
Article History
Received: 23 May 2023
Accepted: 1 August 2023
First Online: 5 September 2023
Declarations
:
: Yoshiya Tanaka received speaking fees and/or honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe, and YL Biologics and received research grants from AbbVie, Asahi-Kasei, Boehringer-Ingelheim, Chugai, Corrona, Daiichi Sankyo, Eisai, Kowa, Mitsubishi-Tanabe, and Takeda. Tsutomu Takeuchi reports receiving grant/research support from AbbVie, Asahi Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Mitsubishi-Tanabe, Shionogi, Takeda, and UCB Japan; serving as a consultant for Astellas, Chugai, and Eli Lilly Japan; and serving on a speakers’ bureau for AbbVie, Ayumi Pharmaceutical Corporation, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Dainippon Sumitomo Eisai, Eli Lilly Japan, Mitsubishi-Tanabe, Novartis, Pfizer Japan, Sanofi, and Gilead Sciences, Inc. Tatsuya Atsumi received research grants, speaking fees, and/or consultancy fees from Gilead Sciences K.K.; Eisai Co., Ltd.; AbbVie Inc.; Alexion Inc.; Asahi-Kasei Co.; Astellas Pharma Inc.; AstraZeneca plc.; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Janssen Pharmaceutical K.K.; Kyowa Kirin Co., Ltd.; Novartis Pharma K.K.; Nippon Boehringer Ingelheim Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Ono Pharmaceutical Co. Ltd.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Teijin Pharma Ltd.; and UCB Japan Co. Ltd. Bernard G. Combe receives grant/research support from Pfizer and Roche-Chugai; and received consulting and/or speaker fees from AbbVie, Bristol-Myers Squibb, Celltrion, Eli Lilly, Gilead-Galapagos, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche-Chugai. Daniel Aletaha reports grants or research support from AbbVie, Merck Sharp & Dohme, Novartis, and Roche; serving as a consultant for Janssen; serving on a speaker’s bureau for Bristol-Myers Squibb, Merck Sharp & Dohme, and UCB; and serving as a consultant and on a speaker’s bureau for AbbVie, Amgen, Celgene, Eli Lilly, Medac, Merck, Novartis, Pfizer, Roche, Sandoz, and Sanofi/Genzyme. Toshihiko Kaise is an employee of Gilead Sciences K.K. and shareholder of Gilead Sciences, Inc. Vijay Rajendran is an employee and shareholder of Galapagos BV.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The study protocols were reviewed and approved by all local institutional review boards or ethics committees of participating institutions. The studies were carried out in accordance with the Declaration of Helsinki and the International Council for Harmonization Good Clinical Practice guidelines. Informed consent to participate was provided by all participants.